Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8WRG

Solution structure of the TAD domain (450-504) of human transcriptional coactivator YAP1

Summary for 8WRG
Entry DOI10.2210/pdb8wrg/pdb
DescriptorTranscriptional coactivator YAP1 (1 entity in total)
Functional Keywordstranscriptional coactivator, transcription factor complex, transcription
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight7048.79
Authors
Zhang, H.,Li, Y. (deposition date: 2023-10-14, release date: 2024-10-16, Last modification date: 2025-05-28)
Primary citationYu, M.,Wang, J.,Zhang, X.,Zhang, H.,Li, C.,Li, J.,Lin, J.,Zheng, J.,Huang, L.,Li, Y.,Sun, S.
The mechanism of YAP/TAZ transactivation and dual targeting for cancer therapy.
Nat Commun, 16:3855-3855, 2025
Cited by
PubMed Abstract: Transcriptional coactivators Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) play key roles in cancers through transcriptional outputs. However, their transactivation mechanisms remain unclear, and effective targeting strategies are lacking. Here, we show that YAP/TAZ possess a hydrophobic transactivation domain (TAD). TAD knockout prevents tumor establishment due to growth defects and enhances immune attack. Mechanistically, TADs facilitate preinitiation complex (PIC) assembly by recruiting the TATA-binding protein-associated factor 4 (TAF4)-dependent TFIID complex and enhance RNA polymerase II (Pol II) elongation through mediator complex subunit 15 (MED15)-dependent mediator recruitment for the expressions of oncogenic/immune-suppressive programs. The synthesized peptide TJ-M11 selectively disrupts TAD interactions with MED15 and TAF4, suppressing tumor growth and sensitizing tumors to immunotherapy. Our findings demonstrate that YAP/TAZ TADs exhibit dual functions in PIC assembly and Pol II elongation via hydrophobic interactions, which represent actionable targets for cancer therapy and combination immunotherapy.
PubMed: 40274828
DOI: 10.1038/s41467-025-59309-w
PDB entries with the same primary citation
Experimental method
SOLUTION NMR
Structure validation

236963

PDB entries from 2025-06-04

PDB statisticsPDBj update infoContact PDBjnumon